⌘K
t
Allergy Therapeutics plc announced on December 16, 2024, that all 16 proposed resolutions at its 2024 Annual General Meeting were duly passed by shareholders. The proxy voting results indicated that all resolutions passed with "For" percentages ranging from 99.68% to 99.99%, and total votes cast for each resolution represented 93.41% of the Issued Share Capital.
| Date | 16 Dec 2024 |
| Time | 15:33:58 |
| Category | AGMs and other meetings |
| ID | 2798Q |
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Result of Annual General Meeting
16 December 2024 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that all resolutions proposed at the 2024 Annual General Meeting ("AGM") held today were duly passed by shareholders on a show of hands.
Resolutions 1 to 13 (inclusive) were proposed as ordinary resolutions and resolutions 14 to 16 (inclusive) were proposed as special resolutions. The results of the proxy votes received ahead of the meeting are outlined in the table below.
|
Resolution |
For: |
%age |
Against: |
%age |
Total Votes Cast |
% of ISC |
Withheld |
|
1. Approval of 2024 Accounts |
4,452,448,269
|
99.99 |
3,624 |
0.01 |
4,452,453,003 |
93.41 |
1,110 |
|
2. Approval of Directors' Remuneration Report |
4,451,072,636
|
99.97
|
1,379,257 |
0.03 |
4,452,453,003 |
93.41 |
1,110 |
|
3. Approval of Directors' Remuneration Policy |
4,438,375,536
|
99.68 |
14,075,557 |
0.32 |
4,452,453,003 |
93.41 |
1,910 |
|
4. To elect Dr. Shaun Furlong as a Director |
4,450,412,573
|
99.99 |
33,283 |
0.01 |
4,452,453,003 |
93.41 |
2,007,147 |
|
5. To elect David Ball as a Director |
4,450,411,773
|
99.99 |
33,283 |
0.01 |
4,452,453,003 |
93.41 |
2,007,947 |
|
6. To re-elect Anthony Parker as a Director |
4,436,433,902
|
99.69 |
14,011,154 |
0.31 |
4,452,453,003 |
93.41 |
2,007,947 |
|
7. To re-elect Zheqing (Simon) Shen as a Director |
4,436,433,902
|
99.69 |
14,011,154 |
0.31 |
4,452,453,003 |
93.41 |
2,007,947 |
|
8. To re-elect Peter Jensen O.B.E. as a Director |
4,436,433,902
|
99.69 |
14,011,154 |
0.31 |
4,452,453,003 |
93.41 |
2,007,947 |
|
9. To re-appoint BDO LLP as auditors of the Company |
4,451,995,528
|
99.99 |
3,624 |
0.01 |
4,452,453,003 |
93.41 |
453,851 |
|
10. To authorise the Directors to agree the Auditors remuneration |
4,452,434,231
|
99.99 |
11,625 |
0.01 |
4,452,453,003 |
93.41 |
7,147 |
|
11. To approve the form of contract and authorise the off-market purchase of deferred shares |
4,452,433,431
|
99.99 |
11,625 |
0.01 |
4,452,453,003 |
93.41 |
7,947 |
|
12. To authorise the Directors to finalise and implement arrangements for the grant of the special, out of cycle, long term incentive awards to the Company's senior executive team and additional option awards to the Company's employees. |
4,436,556,360
|
99.69
|
13,895,533 |
0.31 |
4,452,453,003 |
93.41 |
2,001,110 |
|
13. To authorise the Directors to allot the unissued share capital up to a specific amount (s.551) |
4,452,337,990
|
99.99
|
15,655 |
0.01 |
4,452,453,003 |
93.41 |
99,358 |
|
14. Special Resolution: To authorise the Directors to allot equity securities for cash without first being required to offer such shares to existing shareholders for a period expiring at the conclusion of the next annual general meeting of the Company or 16 March 2026, whichever occurs first. |
4,438,461,319
|
99.69 |
13,892,326 |
0.31 |
4,452,453,003 |
93.41 |
99,358 |
|
15. Special Resolution: To authorise the Directors to allot equity securities and/or sell treasury shares for cash without first being required to offer such securities to existing shareholders. |
4,438,461,319
|
99.69 |
13,892,326 |
0.31 |
4,452,453,003 |
93.41 |
99,358 |
|
16. Special Resolution: To amend the Articles of Association. |
4,450,427,300
|
99.99 |
17,756 |
0.01 |
4,452,453,003 |
93.41 |
2,007,947 |
- ENDS -
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale
Nigel Birks - Life Science Specialist Sales
Tamar Cranford Smith - Sales
+44 (0)20 7220 0500
ICR Healthcare
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.